News Sentiment

ERAS sentiment intelligence

Erasca Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 45 Balanced news tone 67 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 18.53 Week of 10 Jul 2026
Weighted tone 45/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+0.3% over one week, +31.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns

Market Reaction

Balanced read

53/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 0.3% Price digesting
Trend fit Trend active 31.9% over four weeks
Fair value 343.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 39
Negative 17

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
GlobeNewswire 8
Market source 7
simplywall.st 5
PR Newswire 3
Moomoo 3
The Globe and Mail 2
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 31
Regulatory and legal 19
Earnings 10
Balance sheet 3
Analyst action 2
Deals and strategy 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 67
Investing.com Direct company coverage

Erasca closes $632.5 million public stock offering

Erasca Inc. (NASDAQ:ERAS), a precision oncology company, announced the closure of its public offering, raising approximately $632.5 million from the sale of over 36 million common shares at $17.50 each. The proceeds will fund research and development for its product candidates an

Tone
Positive 67/100
Event
Market update
Published
15 Jul 2026 20:40
Source
Investing.com
Moomoo Direct company coverage

Press Release: Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Erasca has announced the closing of its upsized public offering of 33,350,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase additional shares. The offering generated gross proceeds of approximately $100.1 million before deduc

Tone
Positive 72/100
Event
Market update
Published
15 Jul 2026 19:40
Source
Moomoo
TradingView Direct company coverage

Erasca, Inc. Stock 12‑Month Price Target Raised to $21.09, Implies 18% Upside

Analysts have raised the 12-month average price target for Erasca, Inc. (ERAS) stock to $21.45, up from $21.27, suggesting a 20% potential upside from its July 13 closing price. The consensus rating among 11 analysts remains "Buy," with 9 analysts recommending a Buy and 2 recomme

Tone
Positive 84/100
Event
Analyst action
Published
15 Jul 2026 04:40
Source
TradingView
Morningstar Direct company coverage

Erasca, Inc. (ERAS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against Erasca, Inc. (ERAS) for investors who suffered losses. The lawsuit alleges that Erasca failed to disclose that its preclinical data for ERAS-0015 was based on improper comparisons and

Tone
Negative 15/100
Event
Regulatory and legal
Published
15 Jul 2026 04:40
Source
Morningstar
Investing.com Canada Direct company coverage

Form 424B5 Erasca Inc For: 14 July By Investing.com

This article announces the filing of Form 424B5 by Erasca Inc. on July 14, as reported by Investing.com. It is a brief, straightforward notification of a regulatory filing, providing no further details within the article text itself beyond the company name and date of the filing.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
15 Jul 2026 04:15
Source
Investing.com Canada
Stock Titan Direct company coverage

Erasca (Nasdaq: ERAS) prices $550.0M upsized public stock sale

Erasca Inc. (Nasdaq: ERAS) has priced an upsized public offering of 31,428,572 shares of its common stock at $17.50 per share, aiming to raise approximately $550.0 million in gross proceeds. The company plans to use the net proceeds, along with existing cash, to fund research and

Tone
Neutral 50/100
Event
Balance sheet
Published
15 Jul 2026 04:15
Source
Stock Titan
GlobeNewswire Direct company coverage

Erasca, Inc. Notice of August 10, 2026 Application Deadline

Kahn Swick & Foti, LLC (KSF) has notified investors of Erasca, Inc. (NasdaqGS: ERAS) about a class action securities lawsuit. The lawsuit alleges that Erasca and its executives failed to disclose material information regarding the ERAS-0015 product, specifically concerning improp

Tone
Negative 18/100
Event
Regulatory and legal
Published
15 Jul 2026 02:15
Source
GlobeNewswire
Market source Direct company coverage

Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results

Erasca (ERAS) shares surged 8.9% following encouraging Phase 1 clinical trial results for its cancer treatment candidate, ERAS-0015, which showed significant tumor shrinkage in pancreatic cancer patients. Investment firm Jefferies raised its price target for Erasca to $24 and rei

Tone
Positive 75/100
Event
Earnings
Published
15 Jul 2026 01:15
Source
Market source
Quiver Quantitative Direct company coverage

Why Erasca (ERAS) Stock Is Up Today

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 18:36
Source
Quiver Quantitative
Benzinga Direct company coverage

Why Is Erasca Stock Trading Higher Today? - Erasca (NASDAQ:ERAS)

Erasca shares are trading higher today after the company unveiled updated preclinical data for its cancer candidate ERAS-0015, showing encouraging early activity. The company also priced an upsized public offering generating approximately $550 million to fund its pipeline and ope

Tone
Positive 75/100
Event
Market update
Published
14 Jul 2026 18:15
Source
Benzinga
PR Newswire Direct company coverage

The Gross Law Firm Reminds Erasca, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 10, 2026 - ERAS

The Gross Law Firm is reminding investors of Erasca, Inc. (NASDAQ: ERAS) about a pending class action lawsuit with a lead plaintiff deadline of August 10, 2026. The lawsuit alleges that Erasca issued false and misleading statements regarding its ERAS-0015 drug, specifically conce

Tone
Negative 29/100
Event
Regulatory and legal
Published
14 Jul 2026 14:10
Source
PR Newswire
Moomoo Direct company coverage

Press Release: Erasca Announces Pricing of Upsized Public Offering of Common Stock

Erasca has announced the pricing of an upsized public offering of its common stock. The offering is expected to generate significant interest from investors. This move could provide Erasca with additional capital to fund its operations and strategic initiatives.

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 04:15
Source
Moomoo
The Manila Times Direct company coverage

Erasca Announces Pricing of Upsized Public Offering of Common Stock

Erasca, Inc. (Nasdaq: ERAS) has announced the pricing of an upsized public offering of 31,428,572 shares of its common stock at $17.50 per share, expecting gross proceeds of approximately $550.0 million. The clinical-stage oncology company plans to use these proceeds, along with

Tone
Positive 64/100
Event
Market update
Published
14 Jul 2026 03:28
Source
The Manila Times
Stock Titan Direct company coverage

Erasca Plans to Use $550M Offering Proceeds for Drug Development

Erasca (Nasdaq: ERAS) has priced an upsized public offering of 31,428,572 shares of common stock at $17.50 per share, expecting to raise approximately $550 million in gross proceeds. The company plans to use these funds, alongside existing cash, to finance research and developmen

Tone
Neutral 50/100
Event
Balance sheet
Published
14 Jul 2026 03:12
Source
Stock Titan